text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Bitte wählen Sie die Menge aus.

Useful Asymmetric Organoligands for [3+2] Cycloaddition

No.156(January 2013)
D4168
IAP (1)
B3934
PyBidine (2)
IAP (1) and PyBidine (2) are asymmetric organoligands developed by Arai et al. The asymmetric organoligand 1 is found by using a novel high-throughput screening system1) for analyzing the asymmetric induction with circular dichroism as a detector.2) 2 is an asymmetric organoligand having two chiral imidazolidine moieties.3) The structure of an imidazoline, which is usually used as an N-heterocyclic ligand, is nearly planar, while 2 has imidazolidine moieties as ligands instead of imidazoline moieties, which affords a chiral asymmetrical field because of steric hindrance of sp3 carbon on the chiral imidazoline ligand
A copper(I) complex of 1 is highly effective in asymmetric Henry reactions and asymmetric Friedel-Crafts alkylations and the desired products are given in high enantiomeric excess.2) On the other hand, a complex of 2 and copper(II) acts as a catalyst of an asymmetric Mannich reaction.4) Furthermore, asymmetric [3+2]cycloaddition of iminoesters with alkenes can be performed by using the nickel(II) complex of 1, 5) or copper(II) complex of 23) and pyrrolidine cycles are formed with high enantioselectivities. In a case using 1 as a ligand, exo' product is formed, and in a case of 2, the endo one is formed each with high enantioselectivities.

References

The prices are subject to change without notice. Please confirm the newest price by our online catalog before placing an order.
In addition, sales products changes with areas. Please understand that a product is not available when the product details page is not displayed.
Sitzungsstatus
Ihre Sitzung wird in 10 Minuten beendet. Sie werden nach dem Ablauf der Sitzung auf die Startseite umgeleitet. Bitte klicken Sie auf die Schaltfläche, um die Sitzung auf derselben Seite fortzusetzen. Minute beendet. Sie werden nach dem Ablauf der Sitzung auf die Startseite umgeleitet. Bitte klicken Sie auf die Schaltfläche, um die Sitzung auf derselben Seite fortzusetzen.

Deine Sitzung ist abgelaufen. Sie werden auf die Startseite weitergeleitet.